These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1034 related articles for article (PubMed ID: 24179220)

  • 1. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.
    McLellan JS; Chen M; Joyce MG; Sastry M; Stewart-Jones GB; Yang Y; Zhang B; Chen L; Srivatsan S; Zheng A; Zhou T; Graepel KW; Kumar A; Moin S; Boyington JC; Chuang GY; Soto C; Baxa U; Bakker AQ; Spits H; Beaumont T; Zheng Z; Xia N; Ko SY; Todd JP; Rao S; Graham BS; Kwong PD
    Science; 2013 Nov; 342(6158):592-8. PubMed ID: 24179220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative conformations of a major antigenic site on RSV F.
    Jones HG; Battles MB; Lin CC; Bianchi S; Corti D; McLellan JS
    PLoS Pathog; 2019 Jul; 15(7):e1007944. PubMed ID: 31306469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.
    McLellan JS; Chen M; Leung S; Graepel KW; Du X; Yang Y; Zhou T; Baxa U; Yasuda E; Beaumont T; Kumar A; Modjarrad K; Zheng Z; Zhao M; Xia N; Kwong PD; Graham BS
    Science; 2013 May; 340(6136):1113-7. PubMed ID: 23618766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.
    Krarup A; Truan D; Furmanova-Hollenstein P; Bogaert L; Bouchier P; Bisschop IJM; Widjojoatmodjo MN; Zahn R; Schuitemaker H; McLellan JS; Langedijk JPM
    Nat Commun; 2015 Sep; 6():8143. PubMed ID: 26333350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.
    McCool RS; Musayev M; Bush SM; Derrien-Colemyn A; Acreman CM; Wrapp D; Ruckwardt TJ; Graham BS; Mascola JR; McLellan JS
    J Virol; 2023 Oct; 97(10):e0092923. PubMed ID: 37737588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
    Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein.
    Harshbarger W; Abeyrathne PD; Tian S; Huang Y; Chandramouli S; Bottomley MJ; Malito E
    MAbs; 2021; 13(1):1955812. PubMed ID: 34420474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains.
    Lee J; Klenow L; Coyle EM; Golding H; Khurana S
    PLoS Pathog; 2018 Aug; 14(8):e1007262. PubMed ID: 30142227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
    Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML
    Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
    Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
    J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus.
    Stewart-Jones GB; Thomas PV; Chen M; Druz A; Joyce MG; Kong WP; Sastry M; Soto C; Yang Y; Zhang B; Chen L; Chuang GY; Georgiev IS; McLellan JS; Srivatsan S; Zhou T; Baxa U; Mascola JR; Graham BS; Kwong PD
    PLoS One; 2015; 10(6):e0128779. PubMed ID: 26098893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proof of concept for structure-based vaccine design targeting RSV in humans.
    Crank MC; Ruckwardt TJ; Chen M; Morabito KM; Phung E; Costner PJ; Holman LA; Hickman SP; Berkowitz NM; Gordon IJ; Yamshchikov GV; Gaudinski MR; Kumar A; Chang LA; Moin SM; Hill JP; DiPiazza AT; Schwartz RM; Kueltzo L; Cooper JW; Chen P; Stein JA; Carlton K; Gall JG; Nason MC; Kwong PD; Chen GL; Mascola JR; McLellan JS; Ledgerwood JE; Graham BS;
    Science; 2019 Aug; 365(6452):505-509. PubMed ID: 31371616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.